Piramal Pharma is currently trading at Rs. 153.30, up by 3.25 points or 2.17% from its previous closing of Rs. 150.05 on the BSE.
The scrip opened at Rs. 150.00 and has touched a high and low of Rs. 154.70 and Rs. 148.65 respectively. So far 177732 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 161.50 on 06-May-2024 and a 52 week low of Rs. 69.20 on 08-May-2023.
Last one week high and low of the scrip stood at Rs. 161.50 and Rs. 142.00 respectively. The current market cap of the company is Rs. 20280.79 crore.
The promoters holding in the company stood at 35.02%, while Institutions and Non-Institutions held 42.71% and 22.26% respectively.
Piramal Pharma’s Consumer Products Division (CPD) has launched its new digital campaign for 'Polycrol,' its trusted antacid brand, featuring actor, Jisshu Sengupta as the brand ambassador. This collaboration marks a significant milestone in Polycrol's journey to redefine the narrative surrounding digestive wellness.
With a rich legacy spanning over four decades, Polycrol has earned the trust and confidence of millions, establishing itself as the go-to solution for those seeking quick and long lasting relief from acidity. Available in a mint and orange flavor, Polycrol is one of India’s leading liquid antacid brands, and is amongst the top 3 in Eastern India, including West Bengal, Assam and Odisha. It is also available in chewable tablets form.
The campaign's central narrative revolves around a relatable scenario featuring Jisshu Sengupta as a corporate professional constantly prioritizing work over meals, leading to an inevitable encounter with acidity during a crucial presentation. In an era marked by fast-paced lifestyles and erratic eating habits, the campaign emphasizes the brand's reliability and effectiveness in providing timely relief, highlighting its role as a trusted companion in moments of need. Its high action formula starts action in 10 seconds and its highest ANP (Acid Neutralizing Potential) keeps a person relieved for long period of time.
Piramal Pharma provides end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1532.85 |
| Dr. Reddys Lab | 5812.50 |
| Cipla | 1403.90 |
| Zydus Lifesciences | 1104.45 |
| Lupin | 1661.90 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
